ARIX.L

Arix Bioscience Plc
Arix Bioscience Plc - Director/PDMR Shareholding
1st December 2022, 07:45
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 2304I
Arix Bioscience Plc
01 December 2022
 

Arix Bioscience plc
("Company")

PDMR notification & Director Shareholding

The Company announces the annual award of nil cost options to CEO Robert Lyne, which are subject to performance conditions over a three-year assessment period from 1 January 2022 to 31 December 2024 in accordance with the Company's Executive Incentive Plan ("EIP") as disclosed in the Company's Remuneration Policy ("Policy"). Vested Shares are subject to a further two year holding period, as set out in the Policy.

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

Robert Lyne  

2

 

Reason for the notification

 

a)

 

Position/status

 

Chief Executive Officer

b)

 

Initial notification /Amendment

 

Initial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

 

Name

 

Arix Bioscience plc

b)

 

LEI

 

213800OVT3AHQCXNIX43

 

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Arix Bioscience plc Ordinary shares of 0.001 pence each

Identification code

GB00BD045071

b)

 

Nature of the transaction

 

Award of nil-cost options under the Arix Bioscience plc Executive Incentive Plan ("EIP")

 c)

Price(s) and volume(s)


Price(s)

Volume(s)




Nil

 

 

636,792


d)

 

Aggregated information


- Aggregated volume

N/A (Single Transaction)

- Price

N/A (Single Transaction)

e)

 

Date of the transaction

 

30 November 2022

f)

 

Place of the transaction

 

Outside a trading venue

For further information please contact:
Kin Company Secretarial Limited, Company Secretary
 +44 20 8819 6486

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHDFLBBLLLXFBQ ]]>
TwitterFacebookLinkedIn